Sluss P M, Schneyer A L
Department of Urology, University of Rochester Medical Center, New York 14642.
J Clin Endocrinol Metab. 1992 Jun;74(6):1242-6. doi: 10.1210/jcem.74.6.1592865.
Ovarian insensitivity to FSH, as observed in some patients suffering premature ovarian failure (POF), could conceivably involve abnormal regulation of local factors that modulate FSH action. Low molecular weight FSH receptor-binding inhibitor (FRBI) has been identified in ovarian follicular fluid and shown to be an antagonist of FSH action. Thus, we undertook these studies to test the hypothesis that elevated FRBI can account for the high serum levels of FSH as measured by RRA relative to RIA values in some POF patients. In order to accomplish this, 2 POF patients were selected from a group of 27 from whom serum FSH had been measured by RIA and RRA. Using a recently developed and validated RRA, FSH was 430 IU (second IRP-78/549)/L and 182 IU/L for serum from patients 1 and 2, respectively. FSH quantitated by RIA was 96 and 136 IU/L in these same serum samples. Thus, the RRA/RIA values for these patients were 4.48 and 1.34. These ratios are: 1) higher than observed for normal cycling women (0.62); 2) higher than observed for normal, postmenopausal women (0.65); and 3) at least 2 SD higher than the mean RRA/RIA ratio of the 27 patients screened. FRBI was separated from FSH in serum from both these patients. FRBI accounted for most of the elevated FSH measured in serum by RRA. The HPLC chromatographic behavior and binding inhibitory activity of FRBI isolated from a large volume of serum from patient 2 were virtually identical to previously observed characteristics of FRBI isolated from porcine follicular fluid. These observations demonstrate that FRBI can account for elevated FSH measured by RRA relative to that measured by RIA. Furthermore, the inhibitor can be biochemically separated from FSH and quantitated by RRA in order to study its postulated relationship to POF. Expanded studies to identify causal relationships between FRBI and ovarian insensitivity to FSH seem warranted at this time.
在一些患有卵巢早衰(POF)的患者中观察到的卵巢对促卵泡激素(FSH)不敏感,可能涉及调节FSH作用的局部因子的异常调节。已在卵巢卵泡液中鉴定出低分子量FSH受体结合抑制剂(FRBI),并证明它是FSH作用的拮抗剂。因此,我们进行了这些研究,以检验以下假设:相对于某些POF患者通过放射免疫分析(RIA)测得的值,FRBI升高可解释通过放射受体分析(RRA)测得的FSH血清水平升高。为了实现这一点,从27名通过RIA和RRA测量了血清FSH的患者中选择了2名POF患者。使用最近开发并经过验证的RRA,患者1和患者2血清中的FSH分别为430 IU(第二国际参考品-78/549)/L和182 IU/L。在这些相同的血清样本中,通过RIA定量的FSH分别为96 IU/L和136 IU/L。因此,这些患者的RRA/RIA值分别为4.48和1.34。这些比率:1)高于正常月经周期女性的观察值(0.62);2)高于正常绝经后女性的观察值(0.65);3)至少比筛查的27名患者的平均RRA/RIA比率高2个标准差。从这两名患者的血清中分离出FRBI与FSH。FRBI占通过RRA测得的血清中升高的FSH的大部分。从患者2的大量血清中分离出的FRBI的高效液相色谱行为和结合抑制活性与先前从猪卵泡液中分离出的FRBI的观察特征几乎相同。这些观察结果表明,相对于通过RIA测得的FSH,FRBI可以解释通过RRA测得的FSH升高。此外,该抑制剂可以从FSH中进行生化分离,并通过RRA进行定量,以研究其与POF的假定关系。此时似乎有必要进行进一步的研究,以确定FRBI与卵巢对FSH不敏感之间的因果关系。